{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:44:44Z","timestamp":1789757084964,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.pupt.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T12:33:26Z","timestamp":1439210006000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation"],"prefix":"10.1016","volume":"34","author":[{"given":"A.","family":"Planagum\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Calama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aul\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fonquerna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Miralpeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2015.08.002_bib1","series-title":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines Update","year":"2014"},{"key":"10.1016\/j.pupt.2015.08.002_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nri3739","article-title":"The role of airway epithelial cells and innate immune cells in chronic respiratory disease","volume":"14","author":"Holtzman","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pupt.2015.08.002_bib3","doi-asserted-by":"crossref","first-page":"151S","DOI":"10.1378\/chest.121.5_suppl.151S","article-title":"Neutrophils and the pathogenesis of COPD","volume":"121","author":"Stockley","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2015.08.002_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1165\/rcmb.2012-0492TR","article-title":"The neutrophil in chronic obstructive pulmonary disease","volume":"48","author":"Hoenderdos","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.pupt.2015.08.002_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1189\/jlb.0208125","article-title":"The functional significance behind expressing two CXCL8 receptor types on PMN","volume":"86","author":"Stillie","year":"2009","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.pupt.2015.08.002_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMra074111","article-title":"Acute lower respiratory tract infection","volume":"358","author":"Mizgerd","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.pupt.2015.08.002_bib7","doi-asserted-by":"crossref","first-page":"20545","DOI":"10.1074\/jbc.271.34.20545","article-title":"The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor","volume":"271","author":"Ahuja","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.pupt.2015.08.002_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/jpet.106.118927","article-title":"Pharmacological characterization of Sch527123, a potent allosteric CXCR1\/CXCR2 antagonist","volume":"322","author":"Gonsiorek","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pupt.2015.08.002_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/09031936.00048509","article-title":"SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects","volume":"35","author":"Holz","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.08.002_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2125.2011.03968.x","article-title":"SB-656933, a novel CXCR2 selective antagonist, inhibits ex\u00a0vivo neutrophil activation and ozone-induced airway inflammation in humans","volume":"72","author":"Lazaar","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pupt.2015.08.002_bib11","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123-A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","author":"Rennard","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2015.08.002_bib12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.pupt.2015.08.002_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pupt.2015.02.001","article-title":"The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD","volume":"31","author":"Kirsten","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2015.08.002_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jim.2010.11.004","article-title":"Expression of recombinant human interleukin-8 and its purification using a single buffer system","volume":"364","author":"Wiese","year":"2011","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.pupt.2015.08.002_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000186498","article-title":"Differential involvement of Ca2+ and actin filament in leukocyte shape change","volume":"83","author":"Schratl","year":"2009","journal-title":"Pharmacology"},{"key":"10.1016\/j.pupt.2015.08.002_bib16","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1021\/jm0609622","article-title":"Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2\/CXCR1 receptor antagonist","volume":"49","author":"Dwyer","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.pupt.2015.08.002_bib17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bmcl.2009.01.033","article-title":"Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists","volume":"19","author":"Biju","year":"2009","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.pupt.2015.08.002_bib18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1476-5381.2009.00182.x","article-title":"SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor","volume":"158","author":"Bradley","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pupt.2015.08.002_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/13543776.2012.725724","article-title":"Evidence on the identity of the CXCR2 antagonist AZD-5069","volume":"23","author":"Norman","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.pupt.2015.08.002_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0006-2952(03)00459-3","article-title":"Cloning and characterization of guinea pig interleukin-8 receptor","volume":"66","author":"Catusse","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pupt.2015.08.002_bib21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.molimm.2006.03.023","article-title":"Cloning and characterization of guinea pig CXCR1","volume":"44","author":"Takahashi","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.pupt.2015.08.002_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.intimp.2012.04.008","article-title":"LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2","volume":"13","author":"Aul","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.pupt.2015.08.002_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.112.201855","article-title":"Neutrophil chemotaxis caused by COPD alveolar macrophages; the role of CXCL8 and the receptors CXCR1\/CXCR2","volume":"347","author":"Kaur","year":"2013","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pupt.2015.08.002_bib24","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.0800551","article-title":"ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels","volume":"182","author":"Zhao","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.pupt.2015.08.002_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/jpet.114.221358","article-title":"Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist","volume":"353","author":"Nicholls","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pupt.2015.08.002_bib26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1476-5381.2009.00623.x","article-title":"A\u00a0common intracellular allosteric binding site for antagonists of the CXCR2 receptor","volume":"159","author":"Salchow","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pupt.2015.08.002_bib27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1124\/mol.107.044610","article-title":"Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2","volume":"74","author":"Nicholls","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pupt.2015.08.002_bib28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.119040","article-title":"A\u00a0novel, orally active CXCR1\/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation","volume":"322","author":"Chapman","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pupt.2015.08.002_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.intimp.2013.05.029","article-title":"Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist","volume":"17","author":"Seiberling","year":"2013","journal-title":"Int. Immunopharmacol."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:00:41Z","timestamp":1537419641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553915000875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":29,"alternative-id":["S1094553915000875"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2015.08.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}